Perioperative immunotherapy plus chemo for advanced gastric cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stomach or gastroesophageal junction cancer that has not spread to other organs and is considered locally advanced.
- Your tumor has a high level of PD-L1 (CPS ≥ 5), which will be confirmed by a central lab.
- You are between 18 and 80 years old and have an ECOG performance status of 0 or 1 (you are fully active or slightly limited in physical activity).
- You have not received any prior cancer treatment, including immunotherapy like PD-1 or PD-L1 inhibitors.
- Your blood counts and organ function (kidney, liver, heart) are within acceptable ranges, and you do not have active infections or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a new treatment combination for locally advanced stomach cancer. First, you would receive a heated chemotherapy wash inside your abdomen (HIPEC). Then you would get the immunotherapy drug serplulimab plus standard chemotherapy (SOX or XELOX) before surgery, to shrink the tumor and improve outcomes.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) plus chemotherapy to shrink gastric cancer that cannot be surgically removed. The goal is to make the cancer small enough for surgery and improve survival.
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
This trial tests whether adding a short course of radiation to a combination of immunotherapy (PD-1 inhibitor) and chemotherapy (SOX) before surgery helps treat advanced stomach or GEJ cancer. It aims to see if the extra radiation makes the treatment more effective.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.